摘要
目的:针对尼群地平晶I型与晶IV型,建立其混晶原料药中晶型含量的定量分析方法。方法:采用差示扫描量热法,在分别考察晶I型、晶IV型样品质量与热量线性关系的基础上,通过配制尼群地平晶I型与晶IV型的不同含量混晶样品,建立其吸热峰热焓值与晶型含量间的线性关系,实现尼群地平混晶样品中晶型含量的定量分析。结果:尼群地平晶I型与晶IV型的吸热峰Peak值相差2℃,当混晶样品中晶I型含量小于10%或大于40%时,两种晶型的吸热峰无法区分,当混晶样品中晶I型含量在10%~40%范围内时,其含量与热焓具有良好的线性关系。结论:本方法具有试样微量化、操作简单、快速便捷、图谱易于分析等优势,可作为尼群地平晶型质量控制的限量方法使用。
Objective :To establish a quantitative analysis method for the determination of contents of Form I and Form IV nitrendipine in the raw material. Methods:The linea relationship between the quality and heat of Form I and Form IV was investigated first. Mixed crystal samples of nitrendipine with different contents of Form I and Form IV were then prepared. Finally the linear relationship between the enthalpy and polymorphie content was established by differential scanning calorimetry(DSC)method for quantitative analysis of polymorphie content. Re- suits :The temperature difference of endothermie peaks between Form I and Form IV was 2 ℃. When the content of Form I in the mixed crystal was lower than 10% or higher than 40% ,it was impossible to distinguish the two endo- thermic peaks. When the content of Form I in the mixed crystal was between 10% and 40% ,a good linear relation- ship was obtained between the enthalpy of endothermie peaks and crystal contents. Conclusion:The established method is simple,rapid,accurate and easy to analyze,it can be used as a limit control method for nitrendipine poly- morphs.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2015年第12期1423-1426,1434,共5页
Chinese Journal of New Drugs
基金
国家十二五“重大新药创制”科技重大专项(2012ZX09301002-001-013
2013ZX09102110)
关键词
尼群地平
差示扫描量热法
晶型
定量分析
nitrendipine
differential scanning calorimetry
polymorph
quantitative analysis